From global to local: addressing the threat of AMR to STI control
This two-day conference will bring together experts working at the interface of antimicrobial resistance (AMR) and STI research, policy and practice. Themes covered will include surveillance, treatment guidelines, new treatment initiatives, new diagnostic initiatives, antibiotic stewardship, and vaccines.
Anti-microbial resistance (AMR) in sexually transmitted infections (STIs) is a major public health threat, with Neisseria gonorrhoeae being designated as a 鈥渉igh priority antibiotic resistant pathogen鈥 by the World Health Organization (WHO). In the United Kingdom, the recommended that no antibiotics should be prescribed before an appropriate diagnostic test result is available in high-income countries. This is ambitious for the UK, let alone for most low- and middle-income countries where syndromic management is commonplace. In the absence of new diagnostics, antimicrobials and vaccines, combined with limited AMR surveillance data to inform national and global STI programming, there will be serious global sexual and reproductive health consequences.
This two-day conference will bring together experts working at the interface of antimicrobial resistance (AMR) and STI research, policy and practice. Themes covered will include surveillance, treatment guidelines, new treatment initiatives, new diagnostic initiatives, antibiotic stewardship, and vaccines.
The aims of the conference are to:
- Develop a network to share knowledge and experiences of effective strategies and bottlenecks for tackling STI AMR, both locally and globally
- Identify bottlenecks and solutions for tackling STI AMR
- Develop a short- and long-term action plan on STIs and AMR
The conference is being organised by LSHTM鈥檚 STI Research Interest Group (STIRIG), co-hosted with and supported by LSHTM鈥檚 Centre, Public Health England, , and the World Health Organization.
Who should attend?
Anyone interested in AMR and/or STIs, including but not limited to: researchers, healthcare professionals, policy makers, commissioners and service providers.
Presentation slides from speakers can be viewed below:
Welcome
Katy Turner 鈥
Setting The Scene
Magnus Unemo 鈥
Jorgen Jensen 鈥
Surveillance
Michelle Cole 鈥
Gianfranco Spiteri 鈥
Ranmini Kularatne 鈥
Treatment Guidelines
Jorgen Jensen 鈥
Suneeta Soni 鈥
Helen Fifer 鈥
Teodora Wi 鈥
New Treatment Initiatives
Fernando Pascual 鈥
Jonathan Ross 鈥
Antibiotic Stewardship
Esmita Charani 鈥
Nicola Low 鈥
Cecilia Ferreyra 鈥
Achyuta V Nori 鈥
Suzanna Francis 鈥
New Diagnostic Initiatives
Emma Harding-Esch 鈥
Paddy Horner 鈥
Sebastian Fuller 鈥
Vaccines
Suzanna Francis and Emma Harding-Esch 鈥
Sami Gottlieb 鈥
Katy Turner 鈥
Close
Watch the sessions:
Admission
Contact